Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.54 |
| ▸ | HTR2C | P28335 | 7/20 | 0.54 |
| ▸ | HTR2B | P41595 | 5/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 3/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553131 | 0.73 | HTR2C (0.52) | HTR2AHTR2CHTR2BDRD2 | |
| SCHEMBL3560218 | 0.72 | HTR2A (0.55) | HTR2AHTR2CHTR2BSIGMAR1DRD2 | |
| SCHEMBL3560220 | 0.72 | HTR2A (0.55) | HTR2AHTR2CHTR2BSIGMAR1DRD2 | |
| SCHEMBL5582351 | 0.71 | CYP19A1 (0.77) | CYP19A1ACHECYP24A1CYP26A1CYP27A1 | |
| SCHEMBL13119233 | 0.71 | HTR2C (1.00) | HTR2AHTR2CHTR2B | |
| SCHEMBL3558087 | 0.70 | ACHE (0.42) | HTR2AHTR2CHTR2BSIGMAR1DRD2 | |
| SCHEMBL3654185 | 0.67 | DRD2 (0.65) | HTR2AHTR2CHTR2BSIGMAR1DRD2 | |
| SCHEMBL3555389 | 0.67 | HTR2B (0.38) | HTR2AHTR2CHTR2B | |
| SCHEMBL29438690 | 0.67 | GRM5 (0.62) | HTR2AHTR2CHTR2BSIGMAR1DRD2 | |
| SCHEMBL4502402 | 0.67 | GRM5 (0.62) | HTR2AHTR2CHTR2BSIGMAR1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675859-B1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
| US-7812024-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-12 | — | — | US | disclosed |
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-13 | — | — | US | disclosed |
| US-7244843-B2 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-17 | — | — | US | disclosed |
| US-20050080074-A1 | Modulators of serotonin receptors | BRISTOL-MYERS SQUIBB COMPANY | 2005-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213337-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR5A, HTR1A, HTR2A | HTR2A 3/4885HTR2C 5/4885HTR2B 4/4885 |
| US-20050080074-A1 | Modulators of serotonin receptors | HTR5A, HTR1A, HTR2B | HTR2A 4/4885HTR2C 6/4885HTR2B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.